Frontiers in Medicine (Jun 2024)

Research advances in serum chitinase-3-like protein 1 in liver fibrosis

  • Xingwei Hu,
  • Xingwei Hu,
  • Wenhan Liu,
  • Wenhan Liu,
  • Jianhua Liu,
  • Jianhua Liu,
  • Bojian Wang,
  • Bojian Wang,
  • Xiaosong Qin,
  • Xiaosong Qin

DOI
https://doi.org/10.3389/fmed.2024.1372434
Journal volume & issue
Vol. 11

Abstract

Read online

While liver fibrosis remains a serious, progressive, chronic liver disease, and factors causing damage persist, liver fibrosis may develop into cirrhosis and liver cancer. However, short-term liver fibrosis is reversible. Therefore, an early diagnosis of liver fibrosis in the reversible transition phase is important for effective treatment of liver diseases. Chitinase-3-like protein 1 (CHI3L1), an inflammatory response factor that participates in various biological processes and is abundant in liver tissue, holds promise as a potential biomarker for liver diseases. Here, we aimed to review research developments regarding serum CHI3L1 in relation to the pathophysiology and diagnosis of liver fibrosis of various etiologies, providing a reference for the diagnosis, treatment, and prognosis of liver diseases.

Keywords